41st week of 2010 patent applcation highlights part 31 |
Patent application number | Title | Published |
20100260658 | METHOD OF PRODUCING PRE-OXIDATION FIBER AND CARBON FIBER - There is disclosed a method of producing a pre-oxidation fiber in the production of the pre-oxidation fiber by subjecting a polyacrylic precursor fiber to pre-oxidation processing in an oxidizing atmosphere, including shrinking the precursor fiber as a pretreatment of pre-oxidation at a load of 0.58 g/tex or less in the temperature range of 220 to 260° C. under conditions in which the degree of cyclization (I | 2010-10-14 |
20100260659 | BROMINE-FACILITATED SYNTHESIS OF FLUORO-SULFUR COMPOUNDS - Described herein are methods for the bromine-facilitated synthesis of fluoro-sulfur compounds, that include SF | 2010-10-14 |
20100260660 | METHOD FOR PRODUCING CHLORINE BY MULTI STEP ADIABATIC GAS PHASE OXIDATION - The present invention relates to a process for preparing chlorine by catalytic gas phase oxidation of hydrogen chloride with oxygen, in which the reaction is carried out over 18 to 60 catalyst beds connected in series under adiabatic conditions, and to a reactor system for performing the process. | 2010-10-14 |
20100260661 | PREPARATION METHOD OF CHALCOPYRITE-TYPE COMPOUNDS WITH MICROWAVE IRRADIATION - A method for preparing a chalcopyrite-type semiconductor compound which is widely used as a sunlight-absorbing material. More specifically, disclosed is a method for preparing a chalcopyrite-type compound, in which microwaves are used as heat sources in the preparation of the chalcopyrite-type compound, and the chalcopyrite-type compound can be produced in a large amount in a short reaction time using a batch or continuous reactor. | 2010-10-14 |
20100260662 | GROUP II METAL SULFIDE PHOSPHOR PRECURSOR AND METHOD FOR PRODUCING PHOSPHOR - The process of the invention is provided to achieve uniform doping of an activator metal into phosphor particles and to improve efficiency of utlization of a metal element to be used in the production of a Group II metal sulfide phosphor and a precursor thereof. Specifically, the object of the invention is achieved by a process for producing a Group II metal sulfide phosphor precursor, comprising adding to an organic solvent an aqueous solution containing at least one of a Group II element compound, a sulfurizing agent, and a compound containing any of copper, silver, manganese, gold, and rare-earth elements to obtain a reaction mixture, heating the reaction mixture to produce an azeotrope of the water and the organic solvent, and removing the water from the reaction mixture to produce a desired Group II metal sulfide in the reaction mixture, wherein the removal of the water from the reaction mixture is carried out by recovering only the water condensed from a vapor produced by the azeotropic distillation. | 2010-10-14 |
20100260663 | CARBON DIOXIDE FIXATION TO CARBONATES - A high efficiency method or process is provided for converting CO | 2010-10-14 |
20100260664 | Process for Preparing Nano Size Zeolites - A process has been developed to synthesize various zeolites with nano size crystals. The process involves forming an aluminosilicate initiator which exhibits the Tyndall effect and contains no appreciable filterable solids. This initiator is then mixed with a clear solution comprising reactive sources of Al, Si, M and R plus water. M is an alkali or alkaline earth metal while R is an organoammonium compound. The resultant reaction mixture is reacted at a temperature and for a time sufficient to produce a zeolite such as zeolite Y with average crystallite size less than 500 nm or preferably less than 300 nm. | 2010-10-14 |
20100260665 | MOLECULAR SIEVES AND RELATED METHODS AND STRUCTURE DIRECTING AGENTS - Method for preparing molecular sieves and molecular sieves obtained thereby are described. The method includes preparing a reaction mixture, comprising a structure directing agent, at least one source of at least one oxide of a tetravalent element, optionally, one or more sources of one or more oxides selected from the group consisting of oxides of trivalent elements, pentavalent elements, and mixtures thereof, optionally, at least one source of an element selected from Groups 1 and 2 of the Periodic Table; and optionally, hydroxide ions or fluoride ions, and maintaining the reaction mixture under conditions sufficient to form crystals of the molecular sieve. In the method, various imidazolium cations are used as the structure directing element. | 2010-10-14 |
20100260666 | CALCINED UZM-22 AND UZM-22HS ALUMINOSILICATE ZEOLITES - Crystalline microporous zeolites designated calcined UZM-22 and UZM-22HS have been synthesized. The calcined UZM-22 is represented by the empirical formula: | 2010-10-14 |
20100260667 | Vimentin Directed Diagnostics And Therapeutics For Multidrug Resistant Neoplastic Disease - Disclosed are methods for detecting multidrug resistance in neoplastic or damaged cells or multidrug resistant (MDR) neoplastic or damaged cells by detecting an increase in the cell surface expression of vimentin protein in such cells as compared to the level of cell surface expression of vimentin protein in a normal cell or a non-MDR neoplastic cell. | 2010-10-14 |
20100260668 | Dual Variable Domain Immunoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 2010-10-14 |
20100260669 | Treatment of Seasonal Conditions Through Modulation of the Autonomic Nervous System - Multi-dose active agent packages and methods for using the same for treating a subject for a condition are provided. Aspects of the invention include a multi-dose active agent package containing a plurality of unit dosage forms of an active agent configured to modulate at least a portion of a subject's autonomic nervous system during at least one season of the year. The active agent is present in an amount sufficient to alter the parasympathetic activity/sympathetic activity ratio of the subject in a manner effective to treat the subject for the condition. The subject active agent packages and methods find use in the treatment of a variety of different conditions, including disease conditions that increase in severity and/or occurrence during one or more seasons of the year. Also provided are kits for use in practicing the subject methods. | 2010-10-14 |
20100260670 | ALTERNATIVE SPLICE VARIANT PATTERNS OF HUMAN TELOMERASE REVERSE TRANSCRIPTASE (hTERT) IN THYROID TUMORS TO DISTINGUISH BENIGN FROM MALIGNANT - This invention relates, e.g., to a method for determining if a thyroid tumor in a subject is malignant, comprising determining in a sample from the subject the amount of TERT (telomerase reverse transcriptase) mRNA which lacks the β sequence and the amount of TERT mRNA in the sample which comprises the β sequence, wherein a preponderance (e.g., at least about 55%) of TERT mRNA in the sample which comprises the β sequence indicates that the tumor is malignant, and wherein a preponderance of TERT mRNA which lacks the β sequence indicates that the tumor is not malignant. | 2010-10-14 |
20100260671 | COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES - The invention is in general directed to compounds, such as tannic acid, nicotine, nicotine derivatives and pyrrolid derivatives of nicotine, and methods for diagnosing, preventing or alleviating the symptoms of amyloid-associated diseases, for example, neuronal diseases, such as, for example, Alzheimer's disease, compounds and methods for inhibiting ion channel activity of beta amyloid, and methods of diagnostic imaging of A/3 fibrils. | 2010-10-14 |
20100260672 | PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (CMET) AND USES THEREOF - A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed. | 2010-10-14 |
20100260673 | PHAGE DISPLAY PEPTIDE PROBES FOR IMAGING EARLY RESPONSES TO ANTIANGIOGENIC TREATMENT - Rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. Briefly described, embodiments of this disclosure, among others, encompass a class of molecular imaging probes that can predict tumor early responses to anti-angiogenic therapies, such as that based on Bevacizumab (AVASTIN™). In particular, the present disclosure provides peptides that selectively bind to vascularized taget tissues such as, but not limited to solid tumors, responsive to anti-angiogenic therapies and which can, therefore, be useful to selectively concentrate moieties such as detectable labels, or therapeutic agents, in a tumor. The detectable labels, therefore, provide a way to selectively detect and monitor tissues, and most advantageously tumors, that respond to anti-angiogenic therapies. | 2010-10-14 |
20100260674 | QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT - This invention relates to novel quinazoline derivatives, and their pharmaceutically acceptable salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibiting cell surface tyrosine receptor kinases. | 2010-10-14 |
20100260675 | Oxytocin Receptor Antagonists and Their Use for the Treatment of Pulmonary Related Diseases - Methods of treating disorders related to Oxytocin Receptor activity utilize OXYTOCIN RECEPTOR antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, small molecule drugs, siRNA, shRNA, and DNAzymes. Disorders related to Oxytocin Receptor activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD. | 2010-10-14 |
20100260676 | PRECISION-GUIDED NANOPARTICLE SYSTEMS FOR DRUG DELIVERY - A method of preparing multifunctionalized nanoparticles involves using a modular system of half-linkers to attach functional moieties that serve to deliver the nanoparticles to a desired target, exert an effect at the target, or track the nanoparticles within a cell or an animal. The modular chemistry of the half-linker system permits the custom design and synthesis of functionalized nanoparticles bearing multiple groups and therefore results in precise delivery to desired cell types and intracellular locations. The functionalized nanoparticles can be used to treat or diagnose a variety of medical conditions, including neoplastic diseases, infectious diseases, and chronic diseases. | 2010-10-14 |
20100260677 | METHODS AND SYSTEMS FOR TREATMENT AND/OR DIAGNOSIS - The invention relates to methods and systems that can be used for treatment and/or diagnosis. In one aspect, the present invention involves systems and methods for activating a biological cascade in a subject, and administering, to the subject, a composition or a component comprising an agent able to bind a product of a biological cascade or otherwise interact with the biological cascade. The biological cascade may be, for example, a coagulation cascade, a complement cascade, an inflammation cascade, or the like. In some cases, the concentration of a protein, the metabolic demand for a substrate, or the like may be increased as a result of activation of the biological cascade. As a specific non-limiting example, in one set of embodiments, the biological cascade may be a coagulation cascade and the composition administered to the subject may include a fibrin-binding peptide and an antitumor species. By activating the biological cascade, e.g., with an activation composition or by applying energy, coagulation may be induced in a tumor, which the antitumor species may associate with due to an increase in fibrin caused by the coagulation cascade. In addition, in certain aspects, the present invention involves systems and methods for changing tissue from a first state to a second state, for instance, with a first composition comprising nanoparticles. The second composition may be more responsive to the tissue in the second state than in the first state in some cases. In still other aspects, the present invention is generally directed to systems and methods for making such compositions, systems and methods for promoting such compositions, kits involving such compositions, or the like. | 2010-10-14 |
20100260678 | ANTI-IGF-I RECEPTOR ANTIBODIES - Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor. | 2010-10-14 |
20100260679 | METHOD AND APPARATUS FOR DETECTING AND REGULATING VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) BY FORMING A HOMEOSTATIC LOOP EMPLOYING A HALF-ANTIBODY BIOSENSOR - A biosensor for detection of vascular endothelial growth factor (VEGF) hybridization uses an array of parallel capacitors to detect electrochemical binding of circulating VEGF to immobilized anti-VEGF monoclonal half-antibodies (a-VEGF mhAb). Binding of a-VEGF mhAb modulates the threshold voltage of a circuit, changing the impedance of the circuit. An electrode coated with a p-Si substrate enhances the affinity between the VEGF molecules. A fluid cell delivers VEGF samples onto the active surface of the chip. An array of parallel capacitors arranged in an interdigitated pattern detects the VEGF in the fluid. The detector provides an accurately measured and quantifiable rate of change of the VEGF molecules in vivo, providing real time feedback which is used to measure response of the tumor to delivered chemotherapeutic agents and biological response modifiers (BRMs) for the purpose of determining tumor burden and efficacy of the chemotherapy as part of a homeostatic loop for chemotherapy. | 2010-10-14 |
20100260680 | NOVEL BONE MASS INCREASING AGENT - The present invention provides an osteogenesis enhancer comprising a molecule capable of acting on RANKL that enhances differentiation, proliferation, maturation, or calcification of osteoblasts or cells capable of differentiating into osteoblasts. A pharmaceutical composition for treatment or prevention of bone metabolism diseases associated with osteopenia, which comprising, as an active ingredient, a compound that acts on RANKL located on osteoblasts or cells capable of differentiating into osteoblasts and promotes differentiation, proliferation, maturation, or calcification of osteoblasts or cells capable of differentiating into osteoblasts is provided. | 2010-10-14 |
20100260681 | ADRENOCORTICOTROPIC HORMONE ANALOGS AND RELATED METHODS - ACTH analog compounds of the present invention include compounds comprising an ACTH peptide sequence with one or more structural modifications that can have one or more of the following preferred ACTH analog biological functions: (1) reduction of corticosteroid secretion by adrenal membrane in the presence of the ACTH analog compared to unmodified ACTH, (2) reduction of corticosteroid secretion by adrenal membrane in the presence of endogenous ACTH and (3) increased MC-2R binding affinity with reduced activation of the MC-2R receptor compared to unmodified ACTH binding to the MC-2R melanocortin. The ACTH analog compounds of the present invention are therefore useful for treatment or prevention of diseases and disorders related to ACTH, ACTH receptors or corticosteroid secretion, such as premature labor and Cushing's Disease. | 2010-10-14 |
20100260682 | Compounds and methods of use thereof for assaying lysophospholipase D activity - Fluorogenic lysophosphatidic acid derivatives which can be used as substrates in a continuous, fluorogenic assay that can be performed in microtiter plates. The assays permit measuring LysoPLD activity levels in normal events such as pregnancy or disease states such as cancer. In addition, the present invention can be adopted to high throughout screening (HTS) for identification of potential inhibitors of lysoPLD activity. | 2010-10-14 |
20100260683 | THERMOLABILE LIPOSOME WITH CONTROLLED RELEASE TEMPERATURE - The invention relates to a thermolabile liposome with controlled release temperature for the liposome content, which is essentially formed by at least one phosphatidyl choline with a main transition temperature ranging from 0 to 80° C. and 2 to 15 percent by weight of phosphatidyl oligoglycerin. | 2010-10-14 |
20100260684 | USE OF 3-ALKANOYLOXYMETHOXYCARBONYL NITROXIDE ESTERS AS OXIMETRY PROBES FOR MEASUREMENT OF OXYGEN STATUS IN TISSUES - The present invention provides for lipophilic, labile alkanoyloxymethyl esters of nitroxides that cross the blood-brain barrier, and after hydrolysis with esterases therein, the corresponding anionic nitroxides are intracellularly entrapped at levels sufficient to permit O | 2010-10-14 |
20100260685 | CONTRAST AGENTS - The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds of the formula R—Y—X—Z—R where each R denotes a triiodinated phenyl residue further substituted by hydrophilic moieties, Y and Z are urea and urethane groups and X is a alkylene group which may be further substituted. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging, and to contrast media containing such compounds. | 2010-10-14 |
20100260686 | Nanoparticles for brain tumor imaging - Nanoparticle having a chitosan-polyethylene oxide oligomer copolymer coating, and methods for making and using the nanoparticle are provided. The nanoparticle can have a core that includes a material that imparts magnetic resonance imaging activity to the particle and, optionally, one or more of an associated targeting agent, fluorescent agent, or therapeutic agent. | 2010-10-14 |
20100260687 | PERSONAL CARE COMPOSITIONS INCLUDING POLYURETHANE DISPERSIONS - Personal care compositions comprising a high solid aqueous polyurethane dispersion, substantially free of organic solvent and tertiary amines, are described. | 2010-10-14 |
20100260688 | New Formulation and Use Thereof - Provided are liquid pharmaceutical formulations comprising nicotine in any form for administration essentially to the lungs being acidified and/or alkalized by buffering and/or pH regulation providing for a t | 2010-10-14 |
20100260689 | REDUCING SHAVING FREQUENCY - The invention describes the use of acidic aluminum compounds that in cosmetic preparations result in hair softening and a reduction of the shaving frequency. | 2010-10-14 |
20100260690 | STABLE CHEWING GUM COMPOSITIONS COMPRISING MALTITOL AND PROVIDING RAPID RELEASE OF NICOTINE - Use of a nicotine-cellulose combination, maltitol and a gum base for the preparation of a chewing gum composition for achieving a fast onset of nicotine effect after initiation of chewing the chewing gum composition by a subject. The chewing gum composition is preferably prepared by direct compression and it does not disintegrate during chewing. The invention also relates to chewing gum compositions comprising nicotine, which compositions provide a rapid release of nicotine. | 2010-10-14 |
20100260691 | Aqueous compositions containing a hydrophobic material - An aqueous composition containing a hydrophobic material, and, more particularly, a water soluble matrix of a water soluble polymer and a water soluble surfactant, in the form of a complex, for stabilizing the hydrophobic material, as a nanoparticulate dispersion or emulsion. A delivery system for delivering bioactive hydrophobic materials as an aqueous nanoparticle dispersion of a water soluble matrix of polymer and a surfactant. | 2010-10-14 |
20100260692 | MOUTHWASH COMPOSITION COMPRISING XANTHAN GUM AND SODIUM FLUORIDE - An acidic mouthwash is described comprising xanthan gum and an alkali metal fluoride which enhances fluoride uptake into teeth and provides protection against acidic challenges. | 2010-10-14 |
20100260693 | COSMETIC COMPOSITION - A cosmetic composition contains star-shaped zinc oxide particles each having a star shape, and containing zinc oxide as a main substance thereof. | 2010-10-14 |
20100260694 | Methionine Sulfoxide Peptide, Compositions And Methods Of Use - Use of a peptide containing an oxidized methionine residue to ameliorate the effects of oxidative stress in human skin. A short polypeptide containing an oxidized methionine at its C-terminus is shown to inhibit the production of Sunburn Cells in living skin models and to upregulate methionine sulfoxide reductase. Cosmetically acceptable compositions and methods of using the polypeptide are disclosed. The oxidized peptide may repair oxidized alpha | 2010-10-14 |
20100260695 | COMBINATION OF PLANT EXTRACTS TO IMPROVE SKIN TONE - Disclosed is a method of reducing the appearance of uneven skin tone comprising topically applying to skin having an uneven skin tone a composition comprising a combination of the following extracts: | 2010-10-14 |
20100260696 | Aqueous Compositions Containing Alkoxylated Phosphoric Acid Triesters - The invention relates to compositions containing A) at least one phosphoric acid ester of formula (I) | 2010-10-14 |
20100260697 | Composition Containing An Extract of the Fruit of Schisandra Chinensis and Process for Producing Same - A composition including (a) an extract from the fruit of | 2010-10-14 |
20100260698 | Anhydrous Antiperspirant Compositions with Improved Active Substance Release - Antiperspirant compositions for personal body care, ready-made as a stick, soft solid, cream, gel, suspension, solution or impregnated on a substrate, containing at least one antiperspirant active substance, at least one oil, liquid under normal conditions, as a carrier, 0-3 wt. % by weight of free water, based on weight of the composition, and at least one organosiloxane oxyalkylene copolymer. | 2010-10-14 |
20100260699 | Transparent Antiperspirant Gels - Transparent antiperspirant compositions in the form of a water-in-oil emulsion containing a balanced mixture of selected oil components and emulsifiers, thereby improving the antiperspirant effect of the compositions. | 2010-10-14 |
20100260700 | COSMETIC METHOD USING A COMPOSITION COMPRISING A SILOXANE RESIN AND A MINERAL FILLER - The invention relates to a cosmetic method for making up and/or caring for keratinous substances, in particular the skin, comprising the application, to said keratinous substances, of a cosmetic composition comprising a siloxane resin and an inorganic filler. The invention relates in particular to compositions for caring for or making up said keratinous substances. | 2010-10-14 |
20100260701 | COSMETIC METHOD USING A COMPOSITION COMPRISING A SILOXANE RESIN AND A VOLATILE HYDROCARBON-BASED SOLVENT - The invention relates to a cosmetic method for making up and/or caring for keratinous substances, in particular the skin, comprising the application, to said keratinous substances, of a cosmetic composition comprising a siloxane resin and a volatile hydrocarbon solvent. The invention relates in particular to compositions for caring for or making up said keratinous substances. | 2010-10-14 |
20100260702 | BIOABSORBABLE AND BIOCOMPATIBLE POLYURETHANES AND POLYAMIDES FOR MEDICAL DEVICES - Absorbable polyurethanes, polyamides and polyester urethanes prepared from at least one compound selected from: | 2010-10-14 |
20100260703 | INJECTABLE BIODEGRADABLE POLYMER COMPOSITIONS FOR SOFT TISSUE REPAIR AND AUGMENTATION - Methods for soft tissue repair and/or augmentation using injectable, biodegradable polymers are described herein. In one embodiment, the polymer compositions are liquid or pastes at room temperature. In a preferred embodiment, the polymer composition contains liquid or pasty hydroxy fatty acid-based copolyesters, polyester-anhydrides, or combinations thereof. The viscosity of the polymers increases upon contact with bodily fluid to form a solid or semisolid implant suitable for soft tissue repair and/or augmentation. In another embodiment, the polymer composition contains particles of a polymer stereocomplex. One or more active agents may be incorporated into the polymer compositions. Suitable classes of active agents include local anesthetics, anti-inflammatory agents, antibiotics, analgesics, growth factors and agents that induce and/or enhance growth of tissue within the filled cavity or control the growth of a certain type of tissue, and combinations thereof. The polymer compositions may also contain one or more additives or excipients that modify the physical and/or mechanical properties of the polymer. The polymer compositions are typically administered by injection. The injectable polymers can be used for a variety of soft tissue repair and augmentation procedures. | 2010-10-14 |
20100260704 | HUMAN INTERFERON-GAMMA (INFGAMMA) VARIANTS - The present invention relates to human interferon gamma variants with improved thermostability, to a nucleic acid encoding said variants, to a pharmaceutical composition containing them, and to their use for the treatment of a viral infection and of cancer. | 2010-10-14 |
20100260705 | PRODUCTS FOR ALTERING IL-33 ACTIVITY AND METHODS THEREOF - Products for altering IL-33 activity including antibodies that specifically bind to an epitope with the polypeptide sequence of IL-33 such as antibodies that specifically bind to a protease cleavage region of IL-33 comprising the amino acid sequence of SEQ ID No. 17, or SEQ ID NO. 16, or SEQ ID NO. 10; isolated IL-33 polypeptide(s); and compositions comprising a soluble IL-33 receptor linked to an enzyme capable of cleaving IL-33 or an antibody that binds to IL-33 linked to an enzyme capable of cleaving IL-33. The invention also relates to methods of altering IL-33 activity using the products described herein. | 2010-10-14 |
20100260706 | COMPOSITIONS AND METHODS FOR IMPROVING PRODUCTION OF RECOMBINANT POLYPEPTIDES - The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications. | 2010-10-14 |
20100260707 | ANTIGEN ASSOCIATED WITH RHEUMATOID ARTHRITIS - The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis. | 2010-10-14 |
20100260708 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2010-10-14 |
20100260709 | ORGANIC COMPOUNDS AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases. | 2010-10-14 |
20100260710 | MACROCYCLIC SERINE PROTEASE INHIBITORS - Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. | 2010-10-14 |
20100260711 | 3-AMINOSULFONYL SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to 3-Aminosulfonyl Substituted Indole Derivatives, compositions comprising at least one 3-Aminosulfonyl Substituted Indole Derivative, and methods of using the 3-Aminosulfonyl Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 2010-10-14 |
20100260712 | USE OF HUMAN ANTIBODY CAPABLE OF NEUTRALIZING HEPATITIS B VIRUS FOR THE PREVENTION OR TREATMENT OF HEPATITIS B VIRUS INFECTION - The present invention provides a use of a human antibody against a hepatitis B virus (HBV) surface antigen (HBsAg). The antibody exhibits an excellent HBV neutralizing ability, and thus, is useful for the prevention or treatment of the HBV infection or a disease caused thereby. | 2010-10-14 |
20100260713 | Compositions and Methods for the Inhibition of Hepatitis C Viral Replication with Structural Analogs - Compositions and methods for the inhibition of viral replication are provided. In some embodiments, the compositions include a nucleic acid sequence that is identical to a region of the hepatitis C virus (HCV) genome. In other embodiments, the compositions may include a nucleic acid sequence that has at least about 45% to about 95% sequence identity to the native HCV sequence and that has a similar secondary and tertiary structure to the native HCV sequence. In other embodiments, the compositions may include a nucleic acid sequence that does not have significant sequence identity to the native HCV sequence and that has a similar secondary and tertiary structure to the native HCV sequence. Also provided are methods for the treatment of a patient having an HCV infection by administering one of the compositions described herein, and uses of the compositions described herein in the manufacture of a medicament for the inhibition of HCV replication. | 2010-10-14 |
20100260714 | COMPOSITIONS COMPRISING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS AND METHODS OF USE THEREOF - Disclosed are pharmaceutical compositions comprising 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of using such compositions for inhibiting abnormal cell growth or treating hyperproliferative diseases in mammals. | 2010-10-14 |
20100260715 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2010-10-14 |
20100260716 | COMPOUNDS FOR TREATING DEMYELINATION CONDITIONS - Therapeutic methods, therapeutic combinations and pharmaceutical compositions provided herein are useful for inhibiting demyelination, for delaying the clinical onset of a demylination condition, for inhibiting progression and/or reducing frequency of relapse of a demylination condition, and/or enhancing physical ability of a human subject having a demylination condition. Lacosamide is one of the active compounds. | 2010-10-14 |
20100260717 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, AND SCREENING ASSAYS FOR IDENTIFYING COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION - Briefly described, embodiments of this disclosure include compositions, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of identifying a candidate agent for the treatment of hepatitis C virus (HCV) infection, and the like. | 2010-10-14 |
20100260718 | IRF-4 AS A TUMOR SUPPRESSOR AND USES THEREOF - The invention relates to methods for treating BCR/ABL mediated disorders. The methods of the invention also include monitoring progression of or sensitivity to treatment of BCR/ABL mediated disorders as well as identifying subjects for the treatment methods of the invention. Screening assays and related products and kits are also encompassed within the invention. | 2010-10-14 |
20100260719 | METHODS FOR TREATMENT OF HEPATOCELLULAR CARCINOMA USING 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2010-10-14 |
20100260720 | PREVENTION OF OPPORTUNISTIC INFECTIONS IN IMMUNE-COMPROMISED SUBJECTS - This invention relates to a composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals comprising a probiotic | 2010-10-14 |
20100260721 | Enrichment of Cells - The present invention relates to methods of isolating and enriching mesenchymal stem cells (MSCs) comprising treating a tissue sample comprising cells and extracellular matrix with an amount of a collagenase that is sufficient to free MSCs from the extracellular matrix in a liquid medium and then isolating a fraction of the medium containing MSCs. The isolated MSCs can be isolated in surprisingly large numbers such that the fraction can have immediate use in a number of clinical contexts. This represents an advance of prior art techniques that either require the pooling of large volumes of sample tissues from different sources or require MSCs to be expanded in culture. The invention therefore further concerns the clinical use of cells isolated according to the methods of the first aspect of the invention. | 2010-10-14 |
20100260722 | Material for ameliorating skin tissue and method for producing the same - A material for ameliorating skin tissue provided by the invention comprises, as a main component, a culture obtained by culturing cells or tissue fragments derived from human or other mammalian alveolar mucosa. Typically, 50% or more of the cells contained in the culture are fibroblasts, and having a high growth rate and a high productivity in vascular endothelial cell growth factor (VEDF) and/or keratinocyte growth factor (KGF). | 2010-10-14 |
20100260723 | IMPLANTABLE SYSTEM FOR AN INTERVERTEBRAL DISC AND INTERVERTEBRAL DISC IMPLANT - The present invention relates to an implantable system comprising a biologically acceptable bag comprising a cell carrier medium and a multi-component system, the use of such an implantable system for implanting into an intervertebral disc for the treatment of an annulus fibrosus and/or nucleus pulposus defect and/or for preventing an annulus fibrosus and/or nucleus pulposus defect, and an intervertebral disc implant. | 2010-10-14 |
20100260724 | METHOD FOR MEASURING THE PLASMINE ACTIVITY OF MICROPARTICLES PRESENT IN A SAMPLE OF A BIOLOGICAL FLUID AND USE THEREOF - The invention relates to a method for measuring the plasmine activity of microparticles, in particular circulating microparticles, in a sample of a biological fluid, particularly a biological fluid in a flow situation, wherein said method can be used as a diagnosis method or a method for following a treatment. | 2010-10-14 |
20100260725 | Materials and Methods for Treating Allergic and Inflammatory Conditions - The subject invention provides for the utilization of bone-marrow derived stem cells in the treatment of allergic and inflammatory diseases. In one embodiment, the invention provides for treatment of asthma. Bone-marrow derived stem cells can be used for decreasing inflammation and alter the course of immune response in the lung. | 2010-10-14 |
20100260726 | Methods for Producing a Non Human Model for Aortic Aneurysm - The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of said disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof. | 2010-10-14 |
20100260727 | METHOD TO AMPLIFY CARDIAC STEM CELLS IN VITRO AND IN VIVO - Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes. | 2010-10-14 |
20100260728 | METHODS OF PRODUCING PANCREATIC HORMONES - Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy. | 2010-10-14 |
20100260729 | Corn Event PV-ZMIR13 (MON863) Plants and Compositions and Methods for Detection Thereof - The present invention provides compositions and methods for detecting the presence of the corn event MON863 DNA inserted into the corn genome from the transformation of the recombinant construct containing a Cry3Bb gene and of genomic sequences flanking the insertion site. The present invention also provides the corn event MON863 plants, progeny and seeds thereof that contain the corn event MON863 DNA. | 2010-10-14 |
20100260730 | SHIP-Deficiency to Increase Megakaryocyte Progenitor Production - The invention concerns a method for increasing megakaryocyte and megakaryocyte progenitor numbers in vitro or in vivo by suppressing SH2-containing inositol-5-phosphatase (SHIP) function in megakaryocytes or megakaryocyte progenitors expressing the SHIP gene. SHIP function can be suppressed by administering an interfering RNA, or other SHIP inhibitor, to the megakaryocytes or megakaryocyte progenitors in vitro or in vivo. | 2010-10-14 |
20100260731 | PROPAGATION OF PRIMARY CELLS AND THE USE THEREOF - The invention relates to a method for propagating or concentrating primary cells without tumorous characteristics and to the subsequent use thereof. | 2010-10-14 |
20100260732 | ROLE FOR SRY IN PARKINSON'S DISEASE - The present invention relates to a method for treating or preventing Parkinson's disease in a patient, the method comprising administering to the patient a therapeutically effective population of neuronal cells transformed with a nucleic acid molecule encoding SRY, wherein the transformed cells express SRY. | 2010-10-14 |
20100260733 | NOVEL ANTI AGING AGENTS AND METHODS TO IDENTIFY THEM - The present invention discloses novel mechanisms in the aging process and describes novel methods for high-throughput screening to identify, detect, and purify agents to be used for improving mitochondrial function, maintaining the cell cycle-arrested state in senescent and post mitotic cells, and thus preventing or treating age-related diseases or disorders associated with accelerated mitochondrial function loss, telomere dysfunction, and/or deterioration of the growth-arrested state. The present invention also discloses a number of compounds or compositions identified from this method. The present invention further provides the use of low doses of rapamycin or its analogs as a mimic of caloric restriction in preventing age-related diseases or disorders. | 2010-10-14 |
20100260734 | METHOD OF STIMULATING PROSAPOSIN RECEPTOR ACTIVITY - A method for stimulating prosaposin receptor activity in a cell by transfecting the cell with a DNA or RNA molecule encoding prosaposin or a prosaposin receptor agonist. The DNA or RNA molecule is administered either in vivo or used to transfect neural cells or neural stem cells ex vivo followed by reintroduction of the cells into an individual. | 2010-10-14 |
20100260735 | METHODS FOR PROMOTING PLANT HEALTH - A method for promoting the health of a plant comprises administering malic acid to the plant or the soil in an amount effective to recruit plant growth promoting rhizobacteria (PGPR) to the plant. Administration of malic acid promotes biofilm formation of PGPR on the plant's roots, thereby restricting entry of a foliar pathogen through stomatal pores present in the leaves. Another method for promoting the health of a plant comprises administering acetoin to the plant or the soil in an amount effective to increase pathogen resistance in aerial parts of the plant. | 2010-10-14 |
20100260736 | EGR1 MODULATORS FOR THE TREATMENT OF ALOPECIA - An in vitro method of screening of candidate compounds for the preventive or curative treatment of alopecia includes determination of the capacity of a compound to modulate the expression or activity of the Early Growth Response 1 transcription factor (EGR1), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of alopecia; such method also includes in vitro diagnosis or prognosis of this pathology. | 2010-10-14 |
20100260737 | COMBINATION BETWEEN AN ISOTHIOCYANATE AND LEVODOPA FOR PARKINSON'S DISEASE TREATMENT - A combination between levodopa and an extract derived from a vegetable of the Cruciferae family or | 2010-10-14 |
20100260738 | USES AND METHODS RELATING TO NDR KINASE EXPRESSION AND/OR ACTIVITY - The present invention relates to the diagnosis, prognosis or predisposition of developing cancer, especially lymphoma. The invention also relates to gene therapy and identification of potential new therapeutic agents for treating cancer such as lymphoma. | 2010-10-14 |
20100260739 | Mirac Proteins - This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures. | 2010-10-14 |
20100260740 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS - The present invention provides methods for preventing and/or treating lysosomal storage disorders using 5-(fluoromethyl)piperidine-3,4-diol, 5-(chloromethyl)piperidine-3,4-diol, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or any combination of two or more thereof. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease. | 2010-10-14 |
20100260741 | Factor VII or VIIa Polypeptide Variants - The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma. | 2010-10-14 |
20100260742 | Medicament and a method for regulation of the vascular tone - The antibody based medicament contains ultra low doses of monoclonal, polyclonal, immune or natural antibodies to a protein or a peptide involved in the vascular tone regulation or mediating the effects of other regulators; these antibodies are used in activated (potentiated) form produced by multiple subsequent dilution and external impact, preferably in accordance with homeopathic technology. The method of treatment for diseases accompanied by disturbances of the vascular tone utilizes the use of ultra low doses of antibodies to a protein or a peptide involved in the vascular tone regulation or mediating the effects of other regulators; these antibodies are used in activated form produced by multiple subsequent dilution and external impact. | 2010-10-14 |
20100260743 | Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers - There are provided amphiphilic biodegradable copolymers comprising a hydrophilic backbone with pendant aliphatic groups as the hydrophobic component. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors that are capable of solubilizing insoluble organic compounds such as drugs, vitamins, dyes, and imaging agents. The polymers optionally feature reactive functional groups that provide attachment points for antibodies, ligands, and other targeting moieties useful for the targeted delivery of drugs and imaging agents. | 2010-10-14 |
20100260744 | REGULATING IL-4 AND IL-13 LEVELS BY BLOCKING HIGH AFFINITY BINDING BY IL-3, IL-5 AND GM-CSF TO THEIR COMMON RECEPTOR - A method of reducing IL-4 and/or IL-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a βc receptor blocker capable of blocking the binding of all three of IL-3, IL-5 and GM-CSF to the βc common chain to thereby reduce the IL-4 and/or IL-13 levels. | 2010-10-14 |
20100260745 | METHODS OF USING AND CONSTRUCTING NANOSENSOR PLATFORMS - The present invention relates to the use of nanowires, nanotubes and nanosensor platforms. In one embodiment, the present invention provides a method of constructing a nanosensor platform. In another embodiment, the present invention provides a method of analyzing multiple biomarker signals on a nanosensor platform for the detection of a disease. | 2010-10-14 |
20100260746 | Novel Bank1 Splice Variant - The present invention relates to a new splice variant of BANK1, the use of SNPs in BANK1 for diagnostics and the use of antagonists to modulate BANK1 and/or the BANK1 pathway. | 2010-10-14 |
20100260747 | Use of Tetrahydrobiopterin as a Marker and a Therapeutic Agent for Fabry Disease - Blood and tissue markers of the metabolic status, risk of health complications in Fabry disease patients and as a biomarker to follow the efficacy of treatment in animal models and patients with Fabry disease comprising tetrahydrobiopterin (BH4), precursors and metabolites of BH4, and other related co-factors is disclosed herein. The present invention further describes the use of BH4 therapy as a treatment option for Fabry disease to prevent, slow or reverses vascular cardiac and renal manifestations of Fabry disease. | 2010-10-14 |
20100260748 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2010-10-14 |
20100260749 | Modulators of EphA2 and Ephrin-A1 for the treatment of fibrosis-related disease - The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of non-neoplastic hyperproliferative epithelial and/or endothelial cell disorders, including but not limited to disorders associated with increased deposition of extracellular matrix components (e.g., collagen, proteoglycans, tenascin and fibronectin) and/or aberrant angiogenesis. Non-limiting examples of such disorders include cirrhosis, fibrosis (e.g., fibrosis of the liver, kidney, lungs, heart, retina and other viscera), asthma, ischemia, atherosclerosis, diabetic retinopathy, retinopathy of prematurity, vascular restenosis, macular degeneration, rheumatoid arthritis, osteoarthritis, infantile hemangioma, verruca vulgaris, Kaposi's sarcoma, neurofibromatosis, recessive dystrophic epidermolysis bullosa, ankylosing spondylitis, systemic lupus, Reiter's syndrome, Sjogren's syndrome, endometriosis, preeclampsia, atherosclerosis, coronary artery disease, psoriatic arthropathy and psoriasis. The methods of the invention comprise the administration of an effective amount of one or more agents that are modulators of EphA2 and/or its endogenous ligand, EphrinA1. The invention also provides pharmaceutical compositions comprising one or more EphA2/EphrinA1 Modulators of the invention either alone or in combination with one or more other agents useful for therapy for such non-neoplastic hyperproliferative epithelial and/or endothelial disorders. Diagnostic methods and methods for screening for EphA2/EphrinA1 Modulators are also provided. | 2010-10-14 |
20100260750 | Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity - Novel serotonin reuptake inhibitor compounds which are designed to exert serotonin uptake inhibitory activity in the peripheral system while being devoid of CNS activity, and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with peripheral serotonin levels and/or activity, and/or platelet aggregation. | 2010-10-14 |
20100260751 | Methods and Structural Conformations of Antibody Preparations with Increased Resistance to Proteases - Antibody preparations with reduced hydrophobic interactions between Fc side chains and sugar residues of the oligosaccharide backbone present in the CH2 regions of the Fc and/or increased hydrophilic reactions between Fc side chains and sugar residues in the CH2 regions of the Fc-containing protein compared to a wild-type antibody, are prepared by enzymatic treatment, expression under certain conditions, use of particular host cells, and contact with serum. These antibody preparations resist cleavage by proteases, such as papain, ficin, bromolein, pepsin, a matrix metalloproteinase, such as MMP-7, neutrophil elastase (HNE), stromelysin (MMP-3) and macrophage elastase (MMP-12), and glycosylation modification enzymes. | 2010-10-14 |
20100260752 | OPSONIC AND PROTECTIVE ANTIBODIES SPECIFIC FOR LIPOTEICHOIC ACID OF GRAM POSITIVE BACTERIA - This invention provides binding molecules with improved binding affinity to lipoteichoic acids exposed on the surface of the bacteria, useful in the prevention and treatment of infections caused by Gram positive bacteria. | 2010-10-14 |
20100260753 | AMINOFLAVONE (NSC 686288) AND COMBINATIONS THEREOF FOR TREATING BREAST CANCER - Disclosed are methods of treating breast cancer by administering to a mammal aminoflavone, and optionally one or more additional anti-cancer agents. According to example embodiments, the methods include methods of treating cancers resistant to endocrine therapy. | 2010-10-14 |
20100260754 | DKK-1 ANTIBODIES - The invention provides human engineered antibodies, antigen-binding fragments thereof, that bind to, and inhibit the activity of, human DKK-1, and which are effective in treating diseases in which pathogenesis is mediated by DKK-1. | 2010-10-14 |
20100260755 | IBUDILAST AND IMMUNOMODULATORS COMBINATION - The invention contemplates methods and compositions for treating multiple sclerosis including the administration of a PDE inhibitor and at least one immunomodulator comprising mitoxantrone, natalizumab, fingolimod, laquinimod, cladribine, dimethylfumarate or a mixture comprising synthetic polypeptide analogs of myelin basic protein, including alanine, glutamic acid, lysine, and tyrosine amino acid residues, in a therapeutically effective amount. A preferred PDE inhibitor includes ibudilast. | 2010-10-14 |
20100260756 | ANTIBODIES AND RELATED MOLECULES THAT BIND TO 161P2F10B PROTEINS - Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization. | 2010-10-14 |
20100260757 | USE OF PLP WITH PEG-rMETase IN VIVO FOR ENHANCED EFFICACY - This invention relates to methods of modifying pyridoxal 5′ phosphate (PLP) dependent enzymes to extend the serum half-life of the enzyme, extend the in vivo period of methionine depletion in a host, and decrease the immunogenicity of the enzyme. A preferred PLP-dependent enzyme to be modified is a methioninase, preferably a recombinant methioninase (rMETase). The invention further relates to compositions comprising a modified PLP-dependent enzyme and methods of using the same. | 2010-10-14 |